Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.

Current cancer drug targets - 1 Jan 2026

Bayramgil Ayberk, Gunes Tugce Kubra, Ayranci Fatma Gulcicek, Yoruk Atik Duygu, Nigdelioglu Busra, Ozcelik Melike, Dulgar Kaya Ozgecan

Abstract excerpt

INTRODUCTION/BACKGROUND: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases. CASE PRESENTATION: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Mutation

Share to Phenylurea Compounds

Share to Protein Kinase Inhibitors

Share to Pyridines

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Identifiers

PMID: 40390223
DOI: 10.2174/0115680096378189250422100120

Genes

FGFR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.PMID 40390223Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

The evolving role of futibatinib for advanced cholangiocarcinoma.Semantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity Read ↗

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Semantic proximity Read ↗

Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.Semantic proximity Read ↗

FGFR2 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.Semantic proximity Read ↗

Sustained Response on Sequential Anti-fgfr Therapy in Metastatic Gall Bladder Cancer - a Case Report and Literature ReviewSemantic proximity Read ↗

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaSemantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

Biliary cancer: gateway to comprehensive molecular profiling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.